CD11c positive B-chronic lymphocytic leukemia [letter]

CD5+, CD11C+, trap-positive chronic lymphocytic leukemia/prolymphocytic leukemia.

CD11c expression in B-cell chronic lymphocytic leukemia.

Sir, CD79b monoclonal antibody (B29) identifies a Bcell restricted molecule that is part of the mb1/B29 disulphide-linked heterodimer which is non-covalently associated with membrane IgM and IgG to constitute the B-cell antigen receptor complex.1 Both B29 and mb1 are restricted to B-lymphocytes, first appearing on the surface at the pre-B-cell stage and remaining through all stages of B-cell di...

B-cell Chronic Lymphocytic Leukemia

Purpose: To review the recent major advances in the molecular and cell biology of B-cell chronic lymphocytic leukemia (B-CLL). Methods: Weanalyzed thenatureofmalignantB-CLLB cells and their interactions with the microenvironment. Results: B-CLL is a malignancy of a mantle zonebased subpopulation of anergic, self-reactive, activated CD51 B cells devoted to the production of polyreactive natural ...

Alemtuzumab for B-cell chronic lymphocytic leukemia.

Alemtuzumab, a humanized monoclonal antibody, is thought to destroy cancer cells through immune system stimulation or apoptosis induction (programmed cell death). In case series studies using alemtuzumab as salvage therapy, about a third of patients with B-cell chronic lymphocytic leukemia (B-CLL), who were otherwise refractory to chemotherapy, improved. Anti-tumour activity was also observed w...

B lymphocyte subpopulations in chronic lymphocytic leukemia.

We have defined two subpopulations of B lymphocytes in chronic lymphocytic leukemia (CLL). The major variant (termed typical) was characterized by the presence of a relatively homogeneous population of small-to-medium-sized lymphocytes with low-density SmIgM and no evidence of intracellular Ig synthesis. A minor group (termed atypical) was identified by the presence of a pleomorphic cell popula...